Literature DB >> 11078217

The developmental and aging changes of Down's syndrome cell adhesion molecule expression in normal and Down's syndrome brains.

Y Saito1, A Oka, M Mizuguchi, K Motonaga, Y Mori, L E Becker, K Arima, J Miyauchi, S Takashima.   

Abstract

We studied the expression of Down's syndrome cell adhesion molecule (DSCAM) in Down's syndrome (DS) and control brains, using antisera against peptide fragments of DSCAM. On Western blots of human, mouse and rat brain homogenates, the antisera recognized a product at approximately 200 kDa. In the brain of a 2-year-old patient with DS, Western blotting revealed an overexpression of DSCAM compared to an age-matched control. Immunohistochemistry demonstrated DSCAM in the cerebral and cerebellar white matter of both control and DS subjects, in accordance with the temporal and spatial sequence of myelination. In DS brains, immunoreactivity for DSCAM, compared to that for controls, was enhanced in the Purkinje cells at all ages, and in the cortical neurons during adulthood. In demented DS patients, DSCAM immunoreactivity was observed in the core and periphery of senile plaques. The pattern of DSCAM expression suggests that it may play a role as an adhesion molecule regulating myelination. The overexpression of DSCAM may also play a role in the mental retardation and the precocious dementia of DS patients, although the mechanism of neuronal dysfunction is undetermined.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11078217     DOI: 10.1007/s004010000230

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  21 in total

1.  Nuclear import of the DSCAM-cytoplasmic domain drives signaling capable of inhibiting synapse formation.

Authors:  Sonja M Sachse; Sam Lievens; Luís F Ribeiro; Dan Dascenco; Delphine Masschaele; Katrien Horré; Anke Misbaer; Nele Vanderroost; Anne Sophie De Smet; Evgenia Salta; Maria-Luise Erfurth; Yoshiaki Kise; Siegfried Nebel; Wouter Van Delm; Stéphane Plaisance; Jan Tavernier; Bart De Strooper; Joris De Wit; Dietmar Schmucker
Journal:  EMBO J       Date:  2019-02-11       Impact factor: 11.598

2.  DSCAM/PAK1 pathway suppression reverses neurogenesis deficits in iPSC-derived cerebral organoids from patients with Down syndrome.

Authors:  Xiao-Yan Tang; Lei Xu; Jingshen Wang; Yuan Hong; Yuanyuan Wang; Qian Zhu; Da Wang; Xin-Yue Zhang; Chun-Yue Liu; Kai-Heng Fang; Xiao Han; Shihua Wang; Xin Wang; Min Xu; Anita Bhattacharyya; Xing Guo; Mingyan Lin; Yan Liu
Journal:  J Clin Invest       Date:  2021-06-15       Impact factor: 14.808

3.  Synaptic actin stabilization protein loss in Down syndrome and Alzheimer disease.

Authors:  Julie C Lauterborn; Conor D Cox; See Wing Chan; Peter W Vanderklish; Gary Lynch; Christine M Gall
Journal:  Brain Pathol       Date:  2019-09-08       Impact factor: 6.508

4.  Age- and speed-dependent modulation of gaits in DSCAM2J mutant mice.

Authors:  Louise Thiry; Maxime Lemieux; Frédéric Bretzner
Journal:  J Neurophysiol       Date:  2017-11-01       Impact factor: 2.714

5.  Overexpressed Down Syndrome Cell Adhesion Molecule (DSCAM) Deregulates P21-Activated Kinase (PAK) Activity in an In Vitro Neuronal Model of Down Syndrome: Consequences on Cell Process Formation and Extension.

Authors:  Ramón Pérez-Núñez; Natalia Barraza; Arlek Gonzalez-Jamett; Ana Maria Cárdenas; Jean-Vianney Barnier; Pablo Caviedes
Journal:  Neurotox Res       Date:  2016-03-10       Impact factor: 3.911

Review 6.  Making and breaking synapses through local mRNA regulation.

Authors:  Sharon A Swanger; Gary J Bassell
Journal:  Curr Opin Genet Dev       Date:  2011-04-27       Impact factor: 5.578

7.  Frontal white matter integrity in adults with Down syndrome with and without dementia.

Authors:  David Powell; Allison Caban-Holt; Gregory Jicha; William Robertson; Roberta Davis; Brian T Gold; Frederick A Schmitt; Elizabeth Head
Journal:  Neurobiol Aging       Date:  2014-02-04       Impact factor: 4.673

8.  Generation of a panel of antibodies against proteins encoded on human chromosome 21.

Authors:  Frances K Wiseman; Olivia Sheppard; Jacqueline M Linehan; Sebastian Brandner; Victor L J Tybulewicz; Elizabeth M C Fisher
Journal:  J Negat Results Biomed       Date:  2010-08-20

9.  Heart defects and ocular anomalies in children with Down's syndrome.

Authors:  N R Bromham; J M Woodhouse; M Cregg; E Webb; W I Fraser
Journal:  Br J Ophthalmol       Date:  2002-12       Impact factor: 4.638

10.  Apigenin as a Candidate Prenatal Treatment for Trisomy 21: Effects in Human Amniocytes and the Ts1Cje Mouse Model.

Authors:  Faycal Guedj; Ashley E Siegel; Jeroen L A Pennings; Fatimah Alsebaa; Lauren J Massingham; Umadevi Tantravahi; Diana W Bianchi
Journal:  Am J Hum Genet       Date:  2020-10-23       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.